Ruxolitinib Cream Maintains Atopic Dermatitis Control in Children Over 52 Weeks: Phase 3 TRuE-AD3 Trial
Written By : Medha Baranwal
Medically Reviewed By : Dr. Kamal Kant Kohli
USA: Ruxolitinib cream demonstrated sustained disease control and a favourable safety profile over 52 weeks in children aged 2 to 11 years with mild-to-moderate atopic dermatitis (AD), findings from the Phase 3 TRuE-AD3 study. The results suggest that as-needed application of the topical Janus kinase (JAK) inhibitor may help maintain symptom control in children requiring long-term management of the inflammatory skin condition.
The findings were published in the Journal of the American Academy of Dermatology by Amy S. Paller, MD, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA, and colleagues.
Atopic dermatitis is a chronic inflammatory skin disorder characterized by itching, dryness, and recurrent eczema flare-ups. Managing the condition in children often requires long-term treatment to control symptoms while minimizing treatment-related adverse effects. Ruxolitinib cream selectively inhibits JAK1 and JAK2, which are involved in inflammatory signalling pathways contributing to AD.
The initial phase 3 study demonstrated the efficacy and safety of ruxolitinib cream compared with vehicle over eight weeks. The subsequent long-term safety extension evaluated whether disease control could be maintained with intermittent, as-needed application over an additional 44 weeks.
Children aged 2 to 11 years with mild-to-moderate AD who had initially received ruxolitinib cream 0.75% or 1.5% continued using their assigned formulation twice daily as needed. Participants previously treated with vehicle were randomly reassigned to either strength of ruxolitinib cream. Researchers assessed long-term safety and disease control through Week 52.
The analysis revealed the following findings:
- Safety outcomes: Among 282 children receiving ruxolitinib cream during the long-term extension, no new safety concerns emerged. Application-site reactions were reported in 1.1% of participants.
- Treatment-related adverse events: No serious adverse events considered related to treatment were observed during the extension period.
- Disease control: Children initially assigned to ruxolitinib cream 0.75% and 1.5% maintained disease control through Week 52, with Investigator’s Global Assessment scores of 0 or 1 reported in 79.5% and 72.3% of patients, respectively.
- Affected skin area: The mean affected body surface area remained low at 2.0% with the 0.75% formulation and 1.9% with the 1.5% formulation, indicating sustained control of skin involvement.
The researchers acknowledged that the long-term extension did not include a vehicle control group, limiting direct comparisons with untreated or vehicle-treated patients during this period.
The investigators concluded that as-needed ruxolitinib cream was well tolerated and maintained disease control over 44 weeks of extended treatment in children aged 2 to 11 years. The findings were consistent with previously reported results in adolescents and adults, supporting its potential role in long-term topical management of paediatric atopic dermatitis.
Reference:
Paller, A. S., Stein Gold, L. F., Simpson, E. L., Zaenglein, A. L., Armstrong, A. W., Tollefson, M. M., Soong, W., Lee, L. W., Devani, A. R., Forman, S. B., Siri, D. D., Kallender, H., Angel, B., Li, Q., Purohit, V. S., & Eichenfield, L. F. (2026). 52-Week Safety and Disease Control With Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From the Phase 3 TRuE-AD3 Study. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2026.10.072
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.